Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity

Multifocal tumors developed either as independent tumors or as intrahepatic metastases, are very common in primary liver cancer. However, their molecular pathogenesis remains elusive. Herein, a patient with synchronous two hepatocellular carcinoma (HCC, designated as HCC-A and HCC-B) and one intrahepatic cholangiocarcinoma (ICC), as well as two postoperative recurrent tumors, was enrolled. Multiregional whole-exome sequencing was applied to these tumors to delineate the clonality and heterogeneity. The three primary tumors showed almost no overlaps in mutations and copy number variations. Within each tumor, multiregional sequencing data showed varied intratumoral heterogeneity (21.6% in HCC-A, 20.4% in HCC-B, 53.2% in ICC). The mutational profile of two recurrent tumors showed obvious similarity with HCC-A (86.7% and 86.6% respectively), rather than others, indicating that they originated from HCC-A. The evolutionary history of the two recurrent tumors indicated that intrahepatic micro-metastasis could be an early event during HCC progression. Notably, FAT4 was the only gene mutated in two primary HCCs and the recurrences. Mutation prevalence screen and functional experiments showed that FAT4, harboring somatic coding mutations in 26.7% of HCC, could potently inhibit growth and invasion of HCC cells. In HCC patients, both FAT4 expression and FAT4 mutational status significantly correlated with patient prognosis. Together, our findings suggest that spatial and temporal dissection of genomic alterations during the progression of multifocal liver cancer may help to elucidate the basis for its dismal prognosis. FAT4 acts as a putative tumor suppressor that is frequently inactivated in human HCC.

[1]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[2]  W. Lau,et al.  Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: A clinicopathologic study of 35 resected cases , 2013, Journal of gastroenterology and hepatology.

[3]  H. Moch,et al.  Intratumor Heterogeneity in Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[4]  Q. Gao,et al.  Multiple carcinogenesis contributes to the heterogeneity of HCC , 2015, Nature Reviews Gastroenterology &Hepatology.

[5]  R. Marszalek Cancer genomics just got personal , 2014, Genome Biology.

[6]  Motoko Sasaki,et al.  Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C , 2013, Clinical Cancer Research.

[7]  S. Hirohashi,et al.  Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. , 2005, Journal of hepatology.

[8]  L. Goodrich,et al.  Functional interactions between Fat family cadherins in tissue morphogenesis and planar polarity , 2012, Development.

[9]  Charles Swanton,et al.  Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.

[10]  E. Hatano,et al.  Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. , 2014, Gastroenterology.

[11]  X. Wang,et al.  Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning , 2003, Nature Medicine.

[12]  T. Ishikawa Treatment Strategy for Recurrent Multiple Hepatocellular Carcinoma , 2013 .

[13]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[14]  Bin Tean Teh,et al.  Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes , 2012, Nature Genetics.

[15]  Annerose Berndt,et al.  Identification of fat4 and tsc22d1 as novel candidate genes for spontaneous pulmonary adenomas. , 2011, Cancer research.

[16]  Kemp H. Kernstine,et al.  DNA methylation biomarkers for lung cancer , 2011, Tumor Biology.

[17]  M. Katoh,et al.  Function and cancer genomics of FAT family genes , 2012, International journal of oncology.

[18]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[19]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[20]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[21]  D. Calvisi,et al.  New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment , 2014, Hepatology.

[22]  Ching-Lung Lai,et al.  Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy , 2013, Hepatology.

[23]  K. Polyak Tumor Heterogeneity Confounds and Illuminates: A case for Darwinian tumor evolution , 2014, Nature Medicine.

[24]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[25]  J. Zucman‐Rossi,et al.  Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.

[26]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[27]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[28]  Chang Yu,et al.  Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer , 2014, Gut.

[29]  Haitao Luo,et al.  Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. , 2014, Journal of hepatology.

[30]  S. Fan,et al.  Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis , 2003, The Journal of pathology.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[32]  W. Guo,et al.  Nonsynonymous polymorphisms in FAT4 gene are associated with the risk of esophageal cancer in an Eastern Chinese population , 2013, International journal of cancer.

[33]  L. Liau,et al.  Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation , 2013, Nature Genetics.

[34]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[35]  Li Shang,et al.  Genomic and molecular characterization of esophageal squamous cell carcinoma , 2014, Nature Genetics.

[36]  L. Zender,et al.  Primary liver carcinomas can originate from different cell types: a new level of complexity in hepatocarcinogenesis. , 2013, Gastroenterology.

[37]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[38]  Chao Qi,et al.  Identification of Fat4 as a candidate tumor suppressor gene in breast cancers , 2009, International journal of cancer.

[39]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.